Skip to Main Content

Paper Details

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
J Immunother Cancer
6
2021
Author NameAffiliation
Katherine S PanageasMemorial Sloan Kettering Cancer Center
  • 1 - 1

Datasets

Release 1.2